NCT06813742 18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
| NCT ID | NCT06813742 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Condition | Pheochromocytoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2025-12-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2023-05-01 with a primary completion date of 2025-12-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Eligibility Criteria
Inclusion Criteria: 1. Aged 30-80 years old, primary school or above, with a regular caregiver; 2. Clinically diagnosed patients with pheochromocytoma; 3. Can provide informed consent, can understand and comply with the study requirements. Exclusion Criteria: 1. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system; 2. Uncontrolled hypertension or high-risk BP (i.e., systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg); 3. Patients with mental disorders or primary affective disorders; 4. Unable to understand and adhere to the study protocol or provide informed consent; 5. Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.); 6. Allergy to imaging agents; 7. Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06813742 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Pheochromocytoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06813742 currently recruiting?
Yes, NCT06813742 is actively recruiting participants. Contact the research team at wpp199411@163.com for enrollment information.
Where is the NCT06813742 trial being conducted?
This trial is being conducted at Hangzhou, China, Hangzhou, China.
Who is sponsoring the NCT06813742 clinical trial?
NCT06813742 is sponsored by First Affiliated Hospital of Zhejiang University. The trial plans to enroll 80 participants.